Sponsor Dossier
Pfizer (Perth)
Sponsor Dossier for Pfizer (Perth). ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: Aciclovir Intravenous Infusion
- Brand: Atropine
- Brand: Bupivacaine Injection BP
- Brand: Carboplatin Injection
- Brand: Chlorhexidine
- Brand: Cisplatin Injection
- Brand: Cytarabine Injection
- Brand: Daunorubicin Injection
About
Pfizer (Perth) is an Australian Private Company with ABN 32051824956, registered in Western Australia. The company is currently active.
Portfolio
Pfizer (Perth) has 29 brands on the ARTG, with 5 indexable brands. Four brands have at least one PBS-listed item and one brand has PBAC outcome(s) on record. The portfolio includes notable brands such as Aciclovir Intravenous Infusion, Atropine, Bupivacaine Injection BP, Carboplatin Injection, Chlorhexidine, Cisplatin Injection, Cytarabine Injection, Daunorubicin Injection, Docetaxel Pfizer, Doxorubicin, Epirubicin, and Etoposide.
Therapeutic focus
— Complementary Medicine: 26 brands. — Infectious Disease: 1 brand. — Oncology: 1 brand. — Pain Management: 1 brand.
PBS footprint
Four brands have at least one PBS-listed item. The latest PBS schedule date the portfolio touched was 1 May 2026.
Regulatory activity
The most recent PBAC outcome on record is from 1 September 2021. One brand has PBAC outcome(s) on record.